NGNE · Neurogene Inc.

🧪 Trial & FDA Catalysts

• Nov 2028 · Phase 1/2 · Active Trial · Gene Therapy Study for Children With CLN5 Batten Disease
  Registry primary completion date, not a results date
• Dec 2029 · Phase 3 · Active Trial · A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not NGNE's own candidates): Interleukin-2/Interleukin-15 Receptor Agonist NL-201.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NGNE holds $225.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $24.9M/quarter from operations, an estimated runway of 27.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 0 · Low

• Cash runway 27 months
• Company says cash lasts into the first quarter of 2029 -15Following the completion of our July 2, 2026 public offering, we believe our existing cash, cash equivalents and investments will be sufficient to fund our operations into the first quarter of 2029. 10-Q, Aug 2026
• Share count +40% in a year +14

Recent financing filings on SEC EDGAR:

• Nov 4, 2024 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NGNE files for a raise →